Darren Moss

1.3k total citations
30 papers, 904 citations indexed

About

Darren Moss is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Darren Moss has authored 30 papers receiving a total of 904 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 13 papers in Pediatrics, Perinatology and Child Health and 9 papers in Oncology. Recurrent topics in Darren Moss's work include HIV/AIDS drug development and treatment (18 papers), Pharmacological Effects and Toxicity Studies (11 papers) and Drug Transport and Resistance Mechanisms (8 papers). Darren Moss is often cited by papers focused on HIV/AIDS drug development and treatment (18 papers), Pharmacological Effects and Toxicity Studies (11 papers) and Drug Transport and Resistance Mechanisms (8 papers). Darren Moss collaborates with scholars based in United Kingdom, United States and Belgium. Darren Moss's co-authors include Marco Siccardi, Andrew Owen, Stephen A. Ward, Nicholas Fisher, Giancarlo A. Biagini, Paul M. O’Neill, David Back, Neill J. Liptrott, Clare Hoskins and David G. Lalloo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Scientific Reports.

In The Last Decade

Darren Moss

30 papers receiving 896 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Darren Moss United Kingdom 17 324 234 148 143 138 30 904
Neill J. Liptrott United Kingdom 21 440 1.4× 235 1.0× 228 1.5× 232 1.6× 43 0.3× 62 1.2k
Rosa I. Sánchez United States 22 458 1.4× 498 2.1× 303 2.0× 105 0.7× 58 0.4× 50 1.4k
Eri Kanaoka Japan 11 182 0.6× 173 0.7× 85 0.6× 91 0.6× 39 0.3× 15 693
Manisha Ramaswamy Canada 19 169 0.5× 331 1.4× 51 0.3× 304 2.1× 48 0.3× 28 1.0k
Rajith K. R. Rajoli United Kingdom 15 230 0.7× 87 0.4× 119 0.8× 42 0.3× 66 0.5× 29 493
Peidi Hu United States 16 104 0.3× 292 1.2× 40 0.3× 387 2.7× 64 0.5× 21 1.1k
Karl P. Flora United States 16 209 0.6× 251 1.1× 154 1.0× 195 1.4× 24 0.2× 26 897
Jay Dintaman United States 4 114 0.4× 122 0.5× 56 0.4× 224 1.6× 16 0.1× 7 549
Keizo Fukushima Japan 15 85 0.3× 161 0.7× 26 0.2× 140 1.0× 72 0.5× 52 862
Vinay Pandit India 18 136 0.4× 183 0.8× 33 0.2× 22 0.2× 136 1.0× 113 1.1k

Countries citing papers authored by Darren Moss

Since Specialization
Citations

This map shows the geographic impact of Darren Moss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren Moss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren Moss more than expected).

Fields of papers citing papers by Darren Moss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren Moss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren Moss. The network helps show where Darren Moss may publish in the future.

Co-authorship network of co-authors of Darren Moss

This figure shows the co-authorship network connecting the top 25 collaborators of Darren Moss. A scholar is included among the top collaborators of Darren Moss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren Moss. Darren Moss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nassiri, Vahid, Jan Serroyen, Emmanuel Gustin, et al.. (2025). Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity. Toxicology. 514. 154119–154119. 1 indexed citations
2.
Bolleddula, Jayaprakasam, Robert S. Jones, Priyanka Kulkarni, et al.. (2024). Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates. CPT Pharmacometrics & Systems Pharmacology. 14(1). 164–178. 1 indexed citations
3.
Bolleddula, Jayaprakasam, Lionel Cheruzel, Robert S. Jones, et al.. (2023). Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation. Drug Metabolism and Disposition. 51(12). 1591–1606. 6 indexed citations
4.
Jones, Stefanie, Darren Moss, Falko P. Drijfhout, et al.. (2017). Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Scientific Reports. 7(1). 5410–5410. 54 indexed citations
5.
Moss, Darren, et al.. (2017). The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Expert Review of Gastroenterology & Hepatology. 12(3). 223–236. 40 indexed citations
6.
Baptista, Ricardo P., et al.. (2017). Radio Frequency Identification (RFID) as a solution for track and trace of cryogenically-stored cell and gene therapies. Cytotherapy. 19(5). S122–S122. 2 indexed citations
7.
Moss, Darren, et al.. (2017). Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics. 9(4). 39–39. 36 indexed citations
8.
Giardiello, Marco, Neill J. Liptrott, Tom O. McDonald, et al.. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications. 7(1). 13184–13184. 49 indexed citations
9.
Curley, Paul, Rajith K. R. Rajoli, Darren Moss, et al.. (2016). Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico , In Vitro , and In Vivo Investigation. Antimicrobial Agents and Chemotherapy. 61(1). 27 indexed citations
10.
Moss, Darren, Catia Marzolini, Rajith K. R. Rajoli, & Marco Siccardi. (2015). Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opinion on Drug Metabolism & Toxicology. 11(8). 1203–1217. 9 indexed citations
11.
Moss, Darren, Neill J. Liptrott, Marco Siccardi, & Andrew Owen. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Frontiers in Pharmacology. 6. 78–78. 16 indexed citations
12.
Capper, Michael J., Paul M. O’Neill, Nicholas Fisher, et al.. (2015). Antimalarial 4(1H)-pyridones bind to the Q i site of cytochrome bc 1. Proceedings of the National Academy of Sciences. 112(3). 755–760. 73 indexed citations
13.
Moss, Darren, Megan Neary, & Andrew Owen. (2014). The role of drug transporters in the kidney: lessons from tenofovir. Frontiers in Pharmacology. 5. 248–248. 54 indexed citations
14.
Moss, Darren, et al.. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy. 69(12). 3275–3281. 4 indexed citations
15.
Moss, Darren, Marco Siccardi, David Back, & Andrew Owen. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. Journal of Antimicrobial Chemotherapy. 68(7). 1627–1634. 26 indexed citations
16.
Nixon, Gemma L., Darren Moss, Alison E. Shone, et al.. (2013). Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy. 68(5). 977–985. 149 indexed citations
17.
Liptrott, Neill J., Paul Curley, Darren Moss, et al.. (2013). Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation. Journal of Antimicrobial Chemotherapy. 68(11). 2545–2549. 4 indexed citations
18.
Warman, Ashley J., Teresa Rito, Nicholas Fisher, et al.. (2012). Antitubercular pharmacodynamics of phenothiazines. Journal of Antimicrobial Chemotherapy. 68(4). 869–880. 46 indexed citations
19.
Siccardi, Marco, Antonio D’Avolio, Sonia Rodríguez‐Nóvoa, et al.. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. Therapeutic Drug Monitoring. 34(2). 232–235. 27 indexed citations
20.
Moss, Darren, Neill J. Liptrott, Darren Smith, et al.. (2010). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. Antimicrobial Agents and Chemotherapy. 55(2). 879–887. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neill J. Liptrott Breakdown of academic impact, for papers by Rosa I. Sánchez Breakdown of academic impact, for papers by Eri Kanaoka Breakdown of academic impact, for papers by Manisha Ramaswamy Breakdown of academic impact, for papers by Rajith K. R. Rajoli Breakdown of academic impact, for papers by Peidi Hu Breakdown of academic impact, for papers by Karl P. Flora Breakdown of academic impact, for papers by Jay Dintaman Breakdown of academic impact, for papers by Keizo Fukushima Breakdown of academic impact, for papers by Vinay Pandit
Rankless by CCL
2026